The tesamorelin research peptide is a synthetic 44-amino acid growth hormone-releasing hormone (GHRH) analog featuring a trans-3-hexenoic acid modification. Designed for laboratory research use only, this compound is evaluated in vitro and in animal models to investigate pulsatile growth hormone secretion, downstream IGF-1 upregulation, and metabolic regulation.
The tesamorelin research peptide is a synthetic 44-amino acid growth hormone-releasing hormone (GHRH) analog featuring a trans-3-hexenoic acid modification. Designed for laboratory research use only, this compound is evaluated in vitro and in animal models to investigate pulsatile growth hormone secretion, downstream IGF-1 upregulation, and metabolic regulation.
The tesamorelin research peptide is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH 1-44). By incorporating a trans-3-hexenoic acid group at the N-terminal residue, the molecule resists enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), granting it extended biological half-life and enhanced receptor affinity compared to endogenous GHRH.
In laboratory research settings, tesamorelin serves as a primary tool for examining pituitary somatotroph receptor activation, neuroendocrine signaling cascades, and downstream metabolic processes. All analytical data and literature surrounding this molecule pertain strictly to in vitro assays and preclinical animal models; it is strictly intended for scientific evaluation and laboratory research use.
Tesamorelin possesses the chemical formula C221H366N72O67S1 and a molecular mass of approximately 5135.9 Da. Its primary amino acid sequence matches the native human GHRH structure, retaining essential binding domains necessary for high-affinity interaction with the GHRH receptor (GHRHR), a Class B G-protein-coupled receptor primarily expressed on anterior pituitary somatotrophs.
The N-terminal hexenoyl modification plays a crucial structural role. Native GHRH is rapidly cleaved in plasma between the Ala2 and Asp3 position by DPP-4. The hexenoyl moiety blocks DPP-4 recognition without steric interference at the receptor-binding site. Consequently, researchers utilizing the tesamorelin research peptide in cellular assays observe prolonged intracellular cyclic AMP (cAMP) accumulation and sustained signal transduction relative to unmodified sequence fragments.
Upon binding to the GHRH receptor, tesamorelin stimulates the Gs alpha subunit of the receptor complex. This activation triggers adenylyl cyclase, converting adenosine triphosphate (ATP) into cAMP. Elevated intracellular cAMP levels subsequently activate protein kinase A (PKA), driving calcium ion influx via voltage-gated channels and stimulating the transcription of the growth hormone gene.
Preclinical studies suggest that this cascade results in the exocytosis of stored growth hormone (GH) granules from somatotrophic cells. Crucially, because tesamorelin operates through the physiological GHRH pathway rather than ghrelin receptor pathways, it preserves natural negative feedback controls mediated by somatostatin and circulatory insulin-like growth factor 1 (IGF-1). In rodent and non-human primate models, this maintains a pulsatile pattern of GH secretion rather than a sustained, baseline elevation.
A major focus of academic literature involving the tesamorelin research peptide centers on hepatic and peripheral lipid dynamics. Growth hormone exerts direct lipolytic activity by upregulating hormone-sensitive lipase (HSL) and downregulating lipoprotein lipase (LPL) in adipocytes. In vivo animal models evaluating metabolic dysfunction demonstrate significant reductions in visceral adipose tissue (VAT) accumulation following controlled exposure to GHRH analogs.
Furthermore, in vitro hepatocyte models indicate that GHRH receptor activation and subsequent IGF-1 synthesis suppress de novo lipogenesis while accelerating fatty acid beta-oxidation. Research groups frequently utilize tesamorelin to explore cellular pathways involved in non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and systemic insulin sensitivity modulation. Browse our complete catalog of research peptides to review complimentary metabolic assay targets.
Beyond metabolic pathways, elevated circulating IGF-1 concentrations secondary to GHRHR stimulation play an established role in tissue regeneration and cellular proliferation studies. In vitro assays using skeletal muscle progenitor cells (satellite cells) show increased expression of MyoD and myogenin following treatment with IGF-1 pathways, supporting research into myofibrillar protein synthesis and muscle preservation.
Investigational animal models have also highlighted potential neuroprotective mechanisms associated with GHRH signaling. Preclinical studies suggest that GHRH analogs cross or act at the blood-brain barrier interface, influencing neurogenesis, reducing oxidative stress markers, and modulating inflammatory cytokine production in central nervous system microenvironments. Laboratory investigators utilize these models to assess cellular repair across peripheral nerve and cortical tissue cultures.
To understand the relative potency and selectivity of tesamorelin, researchers frequently compare it to other synthetic secretagogues within the GHRH and GHRP classes. While all target the somatotrophic axis, structural differences dictate distinct pharmacokinetic profiles, half-lives, and receptor cross-reactivities.
For example, sermorelin represents the truncated 1-29 sequence of native GHRH without N-terminal modification, resulting in rapid enzymatic cleavage in physiological media. In contrast, cjc-1295 without dac incorporates amino acid substitutions (such as D-Ala2) to resist degradation, yet lacks the specific hexenoyl modification unique to tesamorelin. Meanwhile, compounds like ipamorelin operate via an entirely distinct receptor family—the growth hormone secretagogue receptor (GHSR-1a or ghrelin receptor). Researchers evaluating metabolic specificities often select tesamorelin when pure GHRHR-mediated pathways without ghrelin-driven appetite stimulation are required. Detailed comparative documentation is accessible through our dedicated research portal.
Proper handling and storage protocols are essential to maintain the structural integrity of lyophilized peptides. The tesamorelin research peptide is supplied as a sterile, lyophilized cake designed for laboratory reconstitutions. Lyophilized vials should be kept at -20°C for long-term storage, protected from light and moisture.
For reconstitution in experimental setups, sterile Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl) is introduced down the inner glass wall of the vial to minimize mechanical agitation. Gentle swirling is recommended; vortexing must be avoided as high shear forces can cause peptide aggregation or denaturation. Once reconstituted, solution aliquots remain stable at 2°C to 8°C for a limited duration, typically within 28 days depending on the solvent system and sterility conditions.
Experimental reproducibility requires rigorous verification of compound identity, chemical purity, and freedom from biological contaminants. PX1 Research subjects every batch of synthesized peptides to comprehensive third-party testing at accredited ISO 17025 laboratories.
High-Performance Liquid Chromatography (RP-HPLC) ensures that target purity exceeds 99.0%, confirming the absence of truncated sequences, deletion peptides, or synthesis byproducts. Electrospray Ionization Mass Spectrometry (ESI-MS) validates exact molecular mass against theoretical calculation (5135.9 Da). Additionally, Limulus Amebocyte Lysate (LAL) testing is performed on every production lot to guarantee endotoxin levels remain strictly under <0.1 EU/mg, protecting cellular cultures from lipopolysaccharide-induced inflammatory artifacts.
PX1 Research operates as a trusted USA-based supplier of high-purity research peptides for academic institutions, biotechnology research facilities, and contract research organizations (CROs). All manufacturing adheres to strict GMP-compliant protocols, guaranteeing lot-to-lot consistency across large-scale experimental trials.
Vials are dispatched from specialized logistics centers located in California and Arizona, providing rapid shipping with full temperature control management during transit. Verified researchers and institutional buyers seeking bulk allocations or recurring lot reservations can set up wholesale lab accounts to access direct analytical support and volume fulfillment.
What is the primary target receptor for the tesamorelin research peptide?
Tesamorelin selectively targets and binds to the growth hormone-releasing hormone receptor (GHRHR) located on anterior pituitary somatotroph cells, initiating intracellular cAMP activation.
How does tesamorelin differ structurally from native GHRH?
Tesamorelin contains the full 44-amino acid sequence of human GHRH attached to a trans-3-hexenoic acid group at its N-terminus, rendering it resistant to cleavage by dipeptidyl peptidase-4 (DPP-4).
What analytical methods verify the purity of PX1 Research peptides?
PX1 Research utilizes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity determination (>99.0%) and Electrospray Ionization Mass Spectrometry (ESI-MS) for sequence mass verification.
What are the endotoxin limits for tesamorelin lots supplied by PX1 Research?
Every lot is certified via LAL endotoxin testing to contain less than 0.1 EU/mg, ensuring suitability for sensitive in vitro cell culture and preclinical research assays.
How should lyophilized tesamorelin be stored upon receipt?
Lyophilized vials should be stored in a freezer at -20°C (or -80°C for long-term storage), protected from light exposure, moisture, and frequent freeze-thaw cycles.
Can tesamorelin be reconstituted using standard lab solvents?
Yes, common laboratory reconstituting media include sterile Bacteriostatic Water or 0.9% Sodium Chloride Injection. High-speed vortexing should be avoided to prevent peptide aggregation.
Is tesamorelin suitable for human clinical use or self-administration?
No. All compounds provided by PX1 Research, including tesamorelin, are strictly intended for laboratory research use only by qualified scientific professionals and must not be administered to humans or animals outside of approved research protocols.
Where are PX1 Research compounds manufactured and shipped from?
PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and shipped directly from distribution hubs located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.